Mayling Alvarez Vera

Title: Mayling Alvarez Vera: Innovator in Vaccine Development

Introduction

Mayling Alvarez Vera is a prominent inventor based in Havana, Cuba. She is recognized for her significant contributions to the field of vaccine development, particularly in relation to the dengue virus. Her innovative work has the potential to impact public health positively.

Latest Patents

Alvarez Vera holds a patent for a dengue virus vaccine composition. This vaccine comprises at least one antigen based on the dengue virus (DV) capsid protein and the oligonucleotide identified as SEQ ID NO 1. The composition includes a fusion protein formed by the DV2 capsid and domain III of the envelope protein of the same serotype. This formulation has demonstrated higher levels of cellular immune response and protection in mice compared to previous formulations. The efficacy of these compositions has also been validated in non-human primates. The vaccine can be monovalent, bivalent, or tetravalent and is designed to induce a functional immune response to the four viral serotypes.

Career Highlights

Throughout her career, Mayling Alvarez Vera has worked with notable institutions such as the Centro de Ingeniería Genética y Biotecnología. Her research has focused on developing effective vaccine strategies to combat viral infections, showcasing her dedication to advancing medical science.

Collaborations

Alvarez Vera has collaborated with esteemed colleagues, including Laura Lazo Vazquez and Lázaro López Fernández. These partnerships have contributed to her research and the successful development of her vaccine compositions.

Conclusion

Mayling Alvarez Vera's innovative work in vaccine development, particularly for the dengue virus, highlights her significant contributions to the field of biotechnology. Her research not only advances scientific knowledge but also holds promise for improving public health outcomes.